USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
LIGOCYTE PHARMACEUTICALS, INC.
Address:
LIGOCYTE PHARMACEUTICALS, INC.
2155 Analysis Drive
BOZEMAN, MT 59718 0683
Phone:
(406) 585-2733
URL:
N/A
EIN:
810494034
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,485,761.00 5
SBIR Phase II $2,041,726.00 2
STTR Phase I $205,728.00 1

Award List:

FOOD TEST FOR VEROTOXIN E COLI TO PREVENT INFECTIONS

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$76,274.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

RATIONAL DESIGN OF ADHESION BLOCKING ANTIINFLAMMATORIES

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Nagy, Jon O
Abstract:
N/a

FOOD TEST FOR VEROTOXIN E COLI TO PREVENT INFECTIONS

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$747,372.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Jon O. Nagy
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$1,294,354.00
Agency:
HHS
Principal Investigator:
Jon O. Nagy
Abstract:
N/a

TUBERCLE BACILLI BINDING TO HOST CELLS: VACCINE DESIGN

Award Year / Program / Phase:
2002 / STTR / Phase I
Award Amount:
$205,728.00
Agency:
HHS
Principal Investigator:
Research Institution:
MONTANA STATE UNIVERSITY
RI Contact:
N/A
Abstract:
Three million people die each year from tuberculosis (TB) in spite of the use of the existing anti-mycobacterial antibiotics and the BCG vaccine. Clearly, a better vaccine and better ways to treat TB are needed. The purpose of this STTR Phase I feasibility study is to evaluate Mycobacterium… More

GROUP B STREPTOCOCCAL PEPTIDE MIMETIC VACCINE

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$580,839.00
Agency:
HHS
Principal Investigator:
Abstract:
Group B streptococcus (GBS) causes invasive infections of newborns, pregnant women and adults with underlying medical conditions, such as diabetes or cancer. Despite antibiotic treatment, estimated case fatality rates of 5-20% in neonates and 15-32% in adults establish the prevention of GBS… More

Anthrax Vaccine Formulations Combining PA/Spore Epitopes

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$728,648.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Pulmonary anthrax, a rare but extremely severe form of anthrax, is initiated by phagocytosis of Bacillus anthracis spores by alveolar macrophages (AMs). The current, Protective Antigen (PA) based, vaccine requires several boosts, is reactogenic and its efficacy,… More